MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). - Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; et al. (BMC cancer, 2021)